Legend Biotech Corporation (LEGN)
| Market Cap | 4.98B -19.1% |
| Revenue (ttm) | 1.14B +56.4% |
| Net Income | -250.10M |
| EPS | -1.38 |
| Shares Out | 193.44M |
| PE Ratio | n/a |
| Forward PE | 33.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,983,105 |
| Open | 26.57 |
| Previous Close | 27.08 |
| Day's Range | 25.10 - 26.80 |
| 52-Week Range | 16.24 - 45.30 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | 57.17 (+122.02%) |
| Earnings Date | Aug 10, 2026 |
About LEGN
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lym... [Read more]
Financial Performance
In 2025, Legend Biotech's revenue was $1.03 billion, an increase of 64.02% compared to the previous year's $627.30 million. Losses were -$296.80 million, 67.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for LEGN stock is "Buy." The 12-month stock price target is $57.17, which is an increase of 122.02% from the latest price.
News
Legend Biotech resumed with a Neutral at JPMorgan
JPMorgan resumed coverage of Legend Biotech (LEGN) with a Neutral rating and $35 price target While Carvykti has had a “healthy launch,” JPMorgan struggles to see what near-term event might…
Legend Biotech price target lowered to $63 from $64 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Legend Biotech (LEGN) to $63 from $64 and keeps an Outperform rating on the shares as part of a…
Legend Biotech falls -14.4%
Legend Biotech (LEGN) is down -14.4%, or -$4.82 to $28.70.
Legend Biotech falls -12.2%
Legend Biotech (LEGN) is down -12.2%, or -$4.09 to $29.43.
Legend Biotech 7.7M share Spot Secondary priced at $29.35
Morgan Stanley, Jefferies, Citi and Deutsche Bank are acting as joint book running managers for the offering. The deal priced below last closing price of $33.52.
Legend Biotech Corporation Announces Pricing of Public Offering
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an u...
Legend Biotech secondary offering; price range $29.35-$31.35
Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are serving as joint book-running managers for the offering.
Legend Biotech announces $225M offering of American Depositary Shares
Legend Biotech (LEGN) announced that it has commenced an underwritten public offering of $225M of American Depositary Shares, each representing two ordinary shares of the company. All of the ADSs…
Legend Biotech Corporation Announces Proposed Public Offering
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that it has commenc...
Legend Biotech management to meet with Oppenehimer
Meeting to be held on June 16 hosted by Oppenheimer.
Legend Biotech announces clinical proof-of-concept data for LB2501
Legend Biotech (LEGN) announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell...
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependen...
Legend Biotech announces first clinical proof-of-concept data for LB2501
Legend Biotech (LEGN) announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell...
Legend Biotech price target raised to $49 from $31 at UBS
UBS analyst Ashwani Verma raised the firm’s price target on Legend Biotech (LEGN) to $49 from $31 and keeps a Buy rating on the shares. Early data for Legend’s EHA…
Legend Biotech price target raised to $65 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Legend Biotech (LEGN) to $65 from $50 and keeps a Buy rating on the shares.
This Is Why Legend Biotech Stock (LEGN) Was Up Today
Legend Biotech stock was up on Tuesday alongside positive Phase 1 clinical trial data.
Legend Biotech rises 29.5%
Legend Biotech (LEGN) is up 29.5%, or $7.52 to $33.03.
Legend Biotech presents preliminary clinical data for LB2501 at EHA Congress
Legend Biotech (LEGN) Corporation announced that preliminary clinical data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed/refractory B-c...
Legend's experimental cell therapy shows promise in blood cancer patients
Legend Biotech's experimental therapy showed early signs that its approach of generating disease-fighting cells within patients may work for a type of blood cancer, the company said on Tuesday.
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising prelimin...
Legend Biotech presents first-in-human LB2102 results in solid tumors
Legend Biotech (LEGN) announced first-in-human clinical data for LB2102, its investigational DLL3-targeted CAR-T cell therapy for patients with relapsed or refractory small cell lung cancer or large-c...
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced first-in-human clinica...
Legend Biotech Transcript: American Society of Clinical Oncology (ASCO) Annual Meeting 2026
CARVYKTI demonstrates curative potential in multiple myeloma, with data supporting earlier use for improved survival and safety. Effective bridging strategies and evolving guidelines are reducing toxicity, while real-world evidence and practice patterns show a shift toward second-line use and broader patient access.
Legend Biotech Announces Presentations at ASCO 2026
SOMERSET, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced multiple presentations at t...
Legend Biotech price target lowered to $48 from $49 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Legend Biotech (LEGN) to $48 from $49 and keeps an Overweight rating on the shares.